Matthew Schwee

Cooley advised MapLight Therapeutics, a clinical-stage biopharmaceutical company developing targeted, novel therapies for patients with central nervous system disorders, on its oversubscribed $372.5 million Series D financing.

Cooley advised CallidusAI, Inc., a legal technology startup that developed an artificial intelligence platform for litigation tasks, on securing $10 million in new funding.

Cooley advised FERMÀT, an artificial intelligence-native commerce platform generating brands’ shopping experiences for stronger engagement and conversion, on its $45 million Series B financing round.

Cooley previously advised Impact Analytics, a leader in artificial intelligence (AI)-native innovation and the only provider of an end-to-end platform for pricing, merchandising and supply chain on the close of its Series D funding round led by Blue Cloud Ventures.

Cooley advised Atsena Therapeutics, a clinical-stage gene therapy company developing best-in-class treatments for the reversal or prevention of blindness from inherited retinal diseases, on the close of its oversubscribed $150 million Series C financing.